CRISPR gene-editing drugs manifest beneficial effect in preliminary study

  • Intellia Therapeutics Inc. reported encouraging early-stage study results for its Crispr gene-editing treatments. The path-breaking technology could result in commercially available drugs in the coming years.
  • Intellia said Friday that one of its treatments, code-named NTLA-2002, significantly reduced levels of a protein that causes periodic attacks of swelling in six patients with a rare genetic disease called hereditary angioedema.